Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:08 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 458 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plaque Psoriasis Clear all
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Pruritus, Psoriasis
Interventions
5 mg Serlopitant Tablets, Matching Placebo Tablets
Drug
Lead sponsor
Vyne Therapeutics Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
39
States / cities
Bryant, Arkansas • Beverly Hills, California • Fremont, California + 32 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Psoriatic Plaque
Interventions
KBL697
Drug
Lead sponsor
KoBioLabs
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Birmingham, Alabama • Santa Ana, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
NDI-034858 study drug, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
59
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2023 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
clobetasol propionate spray 0.05%, calcitriol ointment
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years to 80 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
San Diego, California • Newnan, Georgia • Snellville, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2022 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Ruxolitinib phosphate cream, Dovonex® calcipotriene 0.005%, Diprolene® AF betamethasone dipropionate 0.05% cream., Placebo cream
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
6
States / cities
Vallejo, California • Boston, Massachusetts • Rochester, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550, Placebo/CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
32
States / cities
Birmingham, Alabama • Irvine, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
MOL4239, Placebo
Drug
Lead sponsor
Moleculin, LLC
Industry
Eligibility
18 Years to 72 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
3
States / cities
Miami, Florida • Fridley, Minnesota • Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 23, 2014 · Synced May 21, 2026, 8:08 PM EDT
Completed Not applicable Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced May 21, 2026, 8:08 PM EDT
Active, not recruiting Phase 3 Interventional Accepts healthy volunteers
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis, Psoriatic Arthritis
Interventions
bimekizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
CP-690,550
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
2,867 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
101
States / cities
Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2017 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Moderate to Severe Plaque-type Psoriasis
Interventions
Secukinumab (AIN457), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2018 · Synced May 21, 2026, 8:08 PM EDT
Terminated Phase 3 Interventional Results available
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,831 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
67
States / cities
Birmingham, Alabama • Tucson, Arizona • Hot Springs, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2020 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo (fasted), BI 25 mg (fasted), BI 50 mg (fasted), BI 100 mg (fasted), BI 200 mg (fasted), Placebo (fed), BI 400 mg once daily (fed), BI 200 mg twice daily, 400 mg total (fed)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years to 75 Years
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
16
States / cities
Birmingham, Alabama • Los Angeles, California • Santa Ana, California + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2022 · Synced May 21, 2026, 8:08 PM EDT
Terminated Not applicable Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Excimer laser phototherapy
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Tazarotene Cream 0.05%, TAZORAC® (tazarotene) Cream 0.05%, Placebo
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
855 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
30
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Anaheim, California + 25 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Moderate to Severe Chronic Plaque-Type Psoriasis
Interventions
AIN457 150 mg, AIN457 300 mg, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
675 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
28
States / cities
Fresno, California • Pasadena, California • San Francisco, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Clobetasol propionate foam, Vehicle foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Fremont, California • Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 2 Interventional
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
COL-121, 50 µg/g Calcipotriene Ointment, Placebo
Drug
Lead sponsor
Deltanoid Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
20
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced May 21, 2026, 8:08 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
NIS
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 100 Years
Enrollment
899 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
37
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Rogers, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Psoriasis
Interventions
M923, Humira
Biological
Lead sponsor
Momenta Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
572 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
24
States / cities
Beverly Hills, California • Encino, California • La Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Psoriasis
Interventions
Placebo, Adalimumab
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
8
States / cities
Little Rock, Arkansas • Bakersfield, California • Macon, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2010 · Synced May 21, 2026, 8:08 PM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
Interventions
IRX4204, Placebo
Drug · Other
Lead sponsor
Io Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Webster, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Rheumatoid Arthritis, Psoriatic Arthritis, Crohn's Disease, Axial Spondyloarthritis, Plaque Psoriasis
Interventions
Pharmacokinetics of certolizumab pegol
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older · Female only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
3
States / cities
Minneapolis, Minnesota • Durham, North Carolina • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 21, 2026, 8:08 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Plaque-type Psoriasis
Interventions
Placebo, Secukinumab 150mg, Secukinumab 300mg
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
12
States / cities
Phoenix, Arizona • Los Angeles, California • Oceanside, California + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 26, 2018 · Synced May 21, 2026, 8:08 PM EDT